Decreased risk of developing cancer in subjects carrying SLC52A3 rs13042395 polymorphism: proof from a meta-analysis.

ABSTRACT

AIM: This study aimed to conduct a meta-analysis to explore the association between SLC52A3 rs13042395 polymorphism and cancer risk. MATERIALS & METHODS: A comprehensive literature search was performed to confirm the relationship evaluated using STATA 12.0 software. RESULTS: Overall, SLC52A3 rs13042395 C>T polymorphism was associated with cancer risk in two genetic models (TT vs CC odds ratio 0.86; 95% CI 0.80-0.93; p < 0.001, TT vs CC + CT odds ratio 0.88; 95% CI 0.82-0.95; p = 0.001). Significant associations were found between SLC52A3 rs13042395 polymorphism and decreased cancer risk among esophageal cancer, Asians, female, normal BMI and old age groups. No significant associations were observed in alcohol and smoking groups. CONCLUSION: SLC52A3 rs13042395 C>T polymorphism might be a potential biomarker for cancer susceptibility.